InvestorsHub Logo
Followers 2
Posts 2974
Boards Moderated 0
Alias Born 06/23/2017

Re: None

Wednesday, 03/21/2018 7:34:16 PM

Wednesday, March 21, 2018 7:34:16 PM

Post# of 44784
For those that think Celularity are miles behind, take a look at their completed phase 2 trial expecting results in November. Enrolled 182 patients. Have a look at the secondary outcome measures and see if you see anything that looks familiar. And remember, they're sourcing their cells from the placenta as well. The link is at the bottom.

Unlike some that think Gottleib is thinking of us when he speaks, I would be more likely listening to one of his predecessors, that sits on Celularity's board.

Competition is everywhere and in every indication. To dismiss this or say good results from others is good for us, it is not. There are too many big companies with deep pockets and incredibly experienced people. Every month or quarter that passes is critical to our existence. To think otherwise is foolish imo. Time is of the essence. In the very least, this year will be telling as to if this company can survive, or fail. We go through this 1st half with nothing significant, look out.

Contrary to what most would believe, I still have some hope and get encouraged a little when we get these mini increases with higher volumes. We need a sustained increase without a raise at the end of it. The silence this year has got to be the worst I have seen yet in my many years.

I always hope that something leaked to someone, and that is the reason for the sudden move out of no where. No computer trading here sorry. You seriously think any company is going to allow any algorithm to trade this stock, when 99 percent of the time it's down to where it was within a couple days. Not a chance. Maybe to short and even then, extremely unlikely.

Our share price is here because of what is "already known" about this company. IC results better be stellar so we can hopefully partner with some big pharma. Going it alone will be our death sentence imo. Too many big players for a small company to survive on its own, especially with little experience.

Efficacy and Safety of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With and Without Peripheral Arterial Disease

https://clinicaltrials.gov/ct2/show/NCT02264288?term=Celularity&rank=5